Target type: biologicalprocess
The replication of damaged DNA by synthesis across a lesion in the template strand; a specialized DNA polymerase or replication complex inserts a defined nucleotide across from the lesion which allows DNA synthesis to continue beyond the lesion. This process can be mutagenic depending on the damaged nucleotide and the inserted nucleotide. [GOC:elh, GOC:vw, PMID:10535901]
Translesion synthesis (TLS) is a crucial DNA damage tolerance mechanism that allows cells to bypass DNA lesions that block replicative DNA polymerases. These lesions can arise from various sources, including UV radiation, reactive oxygen species, and chemical mutagens. If left unrepaired, such lesions can lead to replication fork stalling, double-strand breaks, and ultimately cell death.
TLS is carried out by specialized DNA polymerases, known as TLS polymerases, which have relaxed active sites that can accommodate damaged DNA bases. These polymerases are distinct from the replicative polymerases that normally copy DNA during S phase. They are recruited to stalled replication forks by specific factors, such as PCNA (proliferating cell nuclear antigen), which acts as a sliding clamp to enhance polymerase processivity.
The process of TLS can be summarized in the following steps:
1. **Replication fork stalling**: When a replicative polymerase encounters a DNA lesion, it is unable to proceed with DNA synthesis, leading to replication fork stalling.
2. **TLS polymerase recruitment**: Specialized TLS polymerases are recruited to the stalled replication fork.
3. **Bypass synthesis**: The TLS polymerase incorporates nucleotides opposite the damaged base, allowing the replication fork to bypass the lesion. This bypass synthesis is often error-prone, as TLS polymerases lack the same fidelity as replicative polymerases.
4. **Switch back to replicative polymerase**: After bypassing the lesion, the TLS polymerase dissociates from the DNA, and the replicative polymerase resumes synthesis.
TLS plays a critical role in maintaining genome integrity, as it allows cells to tolerate DNA damage and complete DNA replication. However, the error-prone nature of TLS can contribute to mutagenesis and cancer development. Therefore, the balance between TLS-mediated DNA damage tolerance and its potential mutagenic consequences is critical for cellular survival and genomic stability.'
"
Protein | Definition | Taxonomy |
---|---|---|
Ubiquitin carboxyl-terminal hydrolase 10 | A ubiquitin carboxyl-terminal hydrolase 10 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q14694] | Homo sapiens (human) |
DNA polymerase iota | A DNA polymerase iota that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9UNA4] | Homo sapiens (human) |
DNA polymerase nu | A DNA polymerase nu that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q7Z5Q5] | Homo sapiens (human) |
Protein mono-ADP-ribosyltransferase PARP10 | A protein mono-ADP-ribosyltransferase PARP10 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q53GL7] | Homo sapiens (human) |
Ubiquitin carboxyl-terminal hydrolase 10 | A ubiquitin carboxyl-terminal hydrolase 10 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q14694] | Homo sapiens (human) |
Transitional endoplasmic reticulum ATPase | A transitional endoplasmic reticulum ATPase that is encoded in the genome of human. [PRO:DNx, UniProtKB:P55072] | Homo sapiens (human) |
Proliferating cell nuclear antigen | A proliferating cell nuclear antigen that is encoded in the genome of human. [PRO:DNx] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
aurintricarboxylic acid | aurintricarboxylic acid : A member of the class of quinomethanes that is 3-methylidene-6-oxocyclohexa-1,4-diene-1-carboxylic acid in which the methylidene hydrogens are replaced by 4-carboxy-3-hydroxyphenyl groups. The trisodium salt is the biological stain 'chrome violet CG' while the triammonium salt is 'aluminon'. Aurintricarboxylic Acid: A dye which inhibits protein biosynthesis at the initial stages. The ammonium salt (aluminon) is a reagent for the colorimetric estimation of aluminum in water, foods, and tissues. | monohydroxybenzoic acid; quinomethanes; tricarboxylic acid | fluorochrome; histological dye; insulin-like growth factor receptor 1 antagonist |
candesartan cilexetil | candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects | biphenyls | |
clotrimazole | conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes | antiinfective agent; environmental contaminant; xenobiotic | |
pj-34 | PJ34 : A member of the class of phenanthridines that is 5,6-dihydrophenanthridine substituted at positions 2 and 6 by (N,N-dimethylglycyl)amino and oxo groups, respectively. It is a potent inhibitor of poly(ADP-ribose) polymerases PARP1 and PARP2 (IC50 of 110 nM and 86 nM, respectively) and exhibits anti-cancer, cardioprotective and neuroprotective properties. | phenanthridines; secondary carboxamide; tertiary amino compound | angiogenesis inhibitor; anti-inflammatory agent; antiatherosclerotic agent; antineoplastic agent; apoptosis inducer; cardioprotective agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; neuroprotective agent |
3,3',5-triiodothyroacetic acid | tiratricol : A monocarboxylic acid that is (4-hydroxy-3,5-diiodophenyl)acetic acid in which the phenolic hydroxy group has been replaced by a 4-hydroxy-3-iodophenoxy group. It is a thyroid hormone analogue that has been used in the treatment of thyroid hormone resistance syndrome. | ||
3,3',5-triiodothyropropionic acid | aromatic ether | ||
thyroxine | thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions. Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism. | 2-halophenol; iodophenol; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid; thyroxine; thyroxine zwitterion | antithyroid drug; human metabolite; mouse metabolite; thyroid hormone |
triiodothyronine | 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism. Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3. | 2-halophenol; amino acid zwitterion; iodophenol; iodothyronine | human metabolite; mouse metabolite; thyroid hormone |
4-Methoxybenzamide | benzamides | ||
3,5-diiodothyronine, (l)-isomer | phenylalanine derivative | ||
3,3'-diiodothyronine | 3,3'-diiodothyronine: RN given refers to unlabeled cpd without isomeric designation | 3,3'-diiodothyronine; amino acid zwitterion | human metabolite |
3,4-dihydro-5-methyl-1(2h)-isoquinolinone | 3,4-dihydro-5-methyl-1(2H)-isoquinolinone: structure given in first source | isoquinolines | |
1-oxo-1,2,3,4-tetrahydroisoquinoline | 1-oxo-1,2,3,4-tetrahydroisoquinoline: structure given in first source | ||
3,5-diiodothyropropionic acid | 3,5-diiodothyropropionic acid : A monocarboxylic acid that is (4-hydroxy-3,5-diiodophenyl)propanoic acid in which the phenolic hydroxy group has been replaced by a 4-hydroxyphenyl group. An ionotropic analogue of L-thyroxine. 3,5-diiodothyropropionic acid: a cardiotonic thyroid hormone analog | aromatic ether; monocarboxylic acid; organoiodine compound; phenols | |
Methylenedioxycinnamic acid | hydroxycinnamic acid | ||
3,4-methylenedioxy-beta-nitrostyrene | 3,4-methylenedioxy-beta-nitrostyrene: tyrosine kinase inhibitor that prevents platelet glycoprotein IIb/IIIa activation; structure in first source | ||
4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol | substituted aniline | ||
ellagic acid | catechols; cyclic ketone; lactone; organic heterotetracyclic compound; polyphenol | antioxidant; EC 1.14.18.1 (tyrosinase) inhibitor; EC 2.3.1.5 (arylamine N-acetyltransferase) inhibitor; EC 2.4.1.1 (glycogen phosphorylase) inhibitor; EC 2.5.1.18 (glutathione transferase) inhibitor; EC 2.7.1.127 (inositol-trisphosphate 3-kinase) inhibitor; EC 2.7.1.151 (inositol-polyphosphate multikinase) inhibitor; EC 2.7.4.6 (nucleoside-diphosphate kinase) inhibitor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; food additive; fungal metabolite; geroprotector; plant metabolite; skin lightening agent | |
rucaparib | AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source | azepinoindole; caprolactams; organofluorine compound; secondary amino compound | antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor |
veliparib | benzimidazoles | EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | |
sch 725680 | Sch 725680: an aazaphilone from Aspergillus sp.; structure in first source | ||
olaparib | cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines | antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | |
niraparib | niraparib : A 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide that has S-configuration. It is a potent inhibitor of PARP1 and PARP2 (IC50 of 3.8 and 2.1 nM, respectively) and approved as a first-line maintenance treatment for women with advanced ovarian cancer after responding to platinum-based chemotherapy. niraparib: structure in first source | 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide | antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; radiosensitizing agent |
ML240 | ML240 : A member of the class of quinazolines that is quinazoline which is substituted at positions 2, 5 and 8 by 2-amino-1H-benzimidazol-1-yl, benzylnitrilo and methoxy groups, respectively. It is a ATP-competetive inhibitor of AAA ATPase p97, also known as valosin-containing protein (VCP). | aromatic amine; aromatic ether; benzimidazoles; primary amino compound; quinazolines; secondary amino compound | antineoplastic agent |
spautin-1 | |||
pinophilin b | pinophilin B: from cultures of a fungus (Penicillium pinophilum Hedgcok) derived from a seaweed; structure in first source | ||
g007-lk | G007-LK: potent and specific small-molecule tankyrase inhibitor; structure in first source | ||
ganciclovir | 2-aminopurines; oxopurine | antiinfective agent; antiviral drug | |
bmn 673 | talazoparib: inhibits both PARP1 and PARP2; structure in first source |